Pharmaceutical

Pfizer touts positive topline data for RSV vaccine Abrysvo

Abrysvo was found to be safe in immunocompromised adults at risk for developing RSV-associated lower respiratory tract disease.

Aug 13, 2024 - 04:00
Pfizer touts positive topline data for RSV vaccine Abrysvo
Abrysvo was found to be safe in immunocompromised adults at risk for developing RSV-associated lower respiratory tract disease.
Read the original article

Tags:

Previous Article

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues

Next Article

Patient with rare neurodegenerative disorder improves with non-profit’s ASO therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novartis and Versant launch Borealis Biosciences with $150m

Novartis and Versant launch Borealis Biosciences with $...

Aug 23, 2024

Amid backlash, Novo Nordisk reports positive cardiovascular profile for Wegovy

Amid backlash, Novo Nordisk reports positive cardiovasc...

Aug 8, 2023

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-...

Sep 18, 2024